Literature DB >> 12411805

Mild hypothermia has minimal effects on the tolerance to severe progressive normovolemic anemia in Swine.

Valéria Perez-de-Sá1, Roger Roscher, Doris Cunha-Goncalves, Anders Larsson, Olof Werner.   

Abstract

BACKGROUND: The benefits of hypothermia during acute severe anemia are not entirely settled. The authors hypothesized that cooling would improve tolerance to anemia.
METHODS: Eight normothermic (38.0 +/- 0.5 degrees C) and eight hypothermic (32.0 +/- 0.5 degrees C) pigs anesthetized with midazolam-fentanyl-vecuronium-isoflurane (0.5% inspired concentration) were subjected to stepwise normovolemic hemodilution (hematocrit, 15%, 10%, 7%, 5%, 3%). Critical hemoglobin concentration (Hgb(CRIT)) and critical oxygen delivery (DO(2CRIT)), i.e., the hemoglobin concentration (Hgb) and oxygen delivery (DO2) at which oxygen consumption (VO2, independently measured by indirect calorimetry) was no longer sustained, and Hgb at the moment of death, defined prospectively as the point when VO2, decreased below 40 ml/min, were used to assess the tolerance of the two groups to progressive isovolemic anemia.
RESULTS: At hematocrits of 15% and 10% (Hgb, 47 and 31 g/l), VO2 was maintained in both groups by an increase (P < 0.001) in cardiac output (CO) and extraction ratio (ER; P< 0.001) with unchanged mean arterial lactate concentration (L(art)). At hematocrit of 7% (Hgb, 22 g/l), all normothermic but no hypothermic animals had DO2-dependent VO2. No normothermic and three hypothermic animals survived to 5% hematocrit (Hgb, 15 g/l), and none survived to 3%. Hgb(CRIT) was 23 +/- 2 g/l and 19 +/- 6 g/l (mean +/- SD) in normothermic and hypothermic animals, respectively (P = 0.053). Hgb at death was 19 +/- 3 g/l versus 14 +/- 4 g/l (P = 0.015), and DO(2CRIT) was 8.7 +/- 1.7 versus 4.6 +/- 0.8 ml x kg(-1) x min(-1) (P < 0.001).
CONCLUSION: During progressive normovolemic hemodilution in pigs, hypothermia did not significantly change Hgb(CRIT), but it decreased the Hgb at death, i.e., short-term survival was prolonged.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411805     DOI: 10.1097/00000542-200211000-00024

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  [Perioperative management of Jehovah's Witness patients. Special consideration of religiously motivated refusal of allogeneic blood transfusion].

Authors:  O Habler; B Voss
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

2.  The choice of the intravenous fluid influences the tolerance of acute normovolemic anemia in anesthetized domestic pigs.

Authors:  Andreas Pape; Saskia Kutschker; Harry Kertscho; Peter Stein; Oliver Horn; Mischa Lossen; Bernhard Zwissler; Oliver Habler
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

3.  Recovery from Extreme Hemodilution (Hemoglobin Level of 0.6 g/dL) in Cadaveric Liver Transplantation.

Authors:  Taro Kariya; Nobuko Ito; Takayuki Kitamura; Yoshitsugu Yamada
Journal:  A A Case Rep       Date:  2015-05-15

4.  Influence of clonidine induced sympathicolysis on anaemia tolerance in anaesthetized pigs.

Authors:  Patrick Lauscher; Harry Kertscho; Malte Krömker; Barbara Haberichter; Kai Zacharowski; Peter Rosenberger; Jens Meier
Journal:  BMC Anesthesiol       Date:  2016-10-12       Impact factor: 2.217

Review 5.  [Tolerance to perioperative anemia. Mechanisms, influencing factors and limits].

Authors:  O Habler; J Meier; A Pape; H Kertscho; B Zwissler
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

6.  Prophylactic hypothermia and neuromuscular blockade to limit myocardial oxygen demand in a critically anemic Jehovah's Witness after emergency surgery†.

Authors:  Michael J Klein; Timothy I Carter; Michael C Smith; Jonathan Wong; Gainosuke Sugiyama
Journal:  J Surg Case Rep       Date:  2014-12-08

7.  [Tolerance to perioperative anemia. Mechanisms, influencing factors and limits].

Authors:  O Habler; J Meier; A Pape; H Kertscho; B Zwissler
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.